Adlai Nortye LTD. (ANL) — SEC Filings

Overview

Adlai Nortye LTD. (ANL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a F-3/A filed on Apr 23, 2026: Adlai Nortye Ltd. filed an amendment (F-3/A) on April 23, 2026, to its registration statement. This filing includes various exhibits such as an indenture, consents from BDO China Shu Lun Pan Certified Public Accountants LLP and Mazars USA LLP, and graphic materials. The company's mailing and busines

Sentiment Summary

Across 20 filings, the sentiment breakdown is: 1 bearish, 19 neutral. The dominant filing sentiment for Adlai Nortye LTD. is neutral.

Filing Type Overview

Adlai Nortye LTD. (ANL) has filed 1 F-3/A, 11 6-K, 2 20-F/A, 2 20-F, 4 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (20)

• Adlai Nortye Ltd. Files F-3/A Amendment — F-3/A · Apr 23, 2026 Risk: medium
  Adlai Nortye Ltd. filed an amendment (F-3/A) on April 23, 2026, to its registration statement. This filing includes various exhibits such as an indenture, conse
• Adlai Nortye Reports H1 2025 Results & Pipeline Update — 6-K · Dec 29, 2025 Risk: medium
  Adlai Nortye Ltd. reported its unaudited first half 2025 financial results and provided an update on its operational progress. The company highlighted its pipel
• Adlai Nortye Ltd. Redomiciles to Singapore, Renames to Adlai Nortye Group Ltd. — 6-K · Dec 3, 2025 Risk: low
  Adlai Nortye Ltd. held its 2025 Extraordinary General Meeting of Shareholders on December 1, 2025, where all proposed resolutions were passed. Shareholders appr
• Adlai Nortye Ltd. Calls Extraordinary General Meeting — 6-K · Oct 22, 2025 Risk: medium
  Adlai Nortye Ltd. filed a Form 6-K on October 22, 2025, to report an upcoming Extraordinary General Meeting of Shareholders. The filing includes the notice of t
• Adlai Nortye Ltd. Adopts 2025 Share Incentive Plan — 6-K · Jul 9, 2025 Risk: low
  Adlai Nortye Ltd. announced the adoption of its 2025 Share Incentive Plan on July 1, 2025. This plan allows the company to grant awards such as options, restric
• Adlai Nortye's Phase III HNSCC Trial Misses Primary Endpoint — 6-K · May 30, 2025 Risk: high
  Adlai Nortye Ltd. announced on May 30, 2025, the topline results of its Phase III BURAN trial for buparlisib (AN2025) in combination with paclitaxel. The trial
• Adlai Nortye Ltd. Files 20-F/A Amendment — 20-F/A · May 12, 2025 Risk: low
  Adlai Nortye Ltd. filed an amendment (20-F/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on May 12, 2025, is an ame
• Adlai Nortye Ltd. Files 2024 Annual Report — 20-F · Apr 30, 2025 Risk: low
  Adlai Nortye Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, operating in the pharmaceutical preparations se
• Adlai Nortye Ltd. Files 20-F/A Amendment — 20-F/A · Feb 14, 2025 Risk: low
  Adlai Nortye Ltd. filed an amendment (20-F/A) to its annual report for the fiscal year ended December 31, 2023. The filing, submitted on February 14, 2025, is a
• Adlai Nortye CFO Resigns, Stays On As Consultant — 6-K · Dec 31, 2024 Risk: medium
  Adlai Nortye Ltd. announced that its Chief Financial Officer, Ms. Vicky Wei Zhang, has resigned effective December 31, 2024, due to personal career development.
• Adlai Nortye Reports H1 2024 Results & New Director — 6-K · Aug 8, 2024 Risk: medium
  Adlai Nortye Ltd. filed a Form 6-K on August 8, 2024, reporting its unaudited financial results for the first half of 2024. The filing also highlighted recent o
• Adlai Nortye CEO & CMO Resigns, Remains Director — 6-K · Jul 3, 2024 Risk: medium
  Adlai Nortye Ltd. announced on July 2, 2024, that Dr. Lars E. Birgerson has resigned as President, Chief Medical Officer, and CEO of its US subsidiary, effectiv
• Adlai Nortye Auditor Mazars Merges with FORVIS — 6-K · Jun 27, 2024 Risk: low
  Adlai Nortye Ltd. announced a change in its independent registered public accounting firm. Mazars USA LLP, the company's auditor, merged with FORVIS, LLP on Jun
• Adlai Nortye to Present AN0025 Data at ASCO 2024 — 6-K · May 24, 2024 Risk: medium
  Adlai Nortye Ltd. announced on May 24, 2024, that it will present encouraging data on the combination of its drug AN0025 with definitive chemoradiotherapy (dCRT
• Adlai Nortye Ltd. Files 20-F Annual Report — 20-F · Apr 19, 2024 Risk: medium
  Adlai Nortye Ltd. (ANL) filed a Foreign Annual Report (20-F) with the SEC on April 19, 2024. Adlai Nortye Ltd. filed its annual report on Form 20-F for the fisc
• Adlai Nortye Appoints Dr. Archie Tse as Head of R&D — 6-K · Apr 2, 2024 Risk: medium
  Adlai Nortye Ltd. announced on April 2, 2024, the appointment of Dr. Archie Tse as the Head of Research & Development. Dr. Tse brings extensive experience in on
• SC 13G Filing — SC 13G · Mar 4, 2024
• SC 13G Filing — SC 13G · Feb 15, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• ATCG Holdings Reports 0% Stake in Adlai Nortye (ANL) — SC 13G · Jan 31, 2024
  ATCG Holdings Ltd. has filed an initial SC 13G, indicating they beneficially own 0 shares of Adlai Nortye Ltd.'s Class A Ordinary Shares as of December 31, 2023

Risk Profile

Risk Assessment: Of ANL's 16 recent filings, 1 were flagged as high-risk, 9 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Yang Lu
• Vicky Wei Zhang
• Dr. Lars E. Birgerson
• Dr. Kaiyang (Tom) Tang
• Dr. Archie Tse

Top Tags

amendment (3) · corporate-governance (3) · annual-report (3) · financial-results (2) · oncology (2) · sec-filing (2) · pharmaceuticals (2) · management-change (2) · registration-statement (1) · securities-offering (1)

Key Numbers

• Filing Date: 2026-04-23 — Date of the F-3/A amendment filing
• Fiscal Year End: 2024 — The report covers the financial performance up to this year.
• SEC File Number: 001-41773 — Identifies the company's filings with the SEC.
• Revenue: 40440000 — Reported revenue figure
• Net Income: 14560000 — Reported net income figure

Related Companies

ADLY

Frequently Asked Questions